新辅助内分泌治疗绝经后乳腺癌的临床疗效观察

目的 观察和探讨新辅助内分泌治疗绝经后乳腺癌的临床疗效和应用价值.方法 对56例绝经后乳腺癌患者应用新辅助内分泌治疗,疗效达CR（完全缓解）、PR（部分缓解）或SD（稳定）则继续进行治疗,直至病情出现PD（进展）或主动提出终止内分泌治疗,再给予手术治疗.结果 所有患者中CR 6例,PR 29例,总有效率（CR＋PR）为62.5%;不同受体阳性患者中,以ER、PR双阳性疗效最好,有效率为78.38%.结论 新辅助内分泌治疗用于治疗绝经后激素受体阳性的乳腺癌患者有明显疗效,副作用小,具有在临床上推广的价值.

The clinical curative effect of neoadjuvant endocrine therapy postmenopausal breast cancer

Objective To observation and explore neoadjuvant endocrine therapy the clinical curative effect of post - menopausal breast cancer and application value. Methods 56 eases postmenopansal breast cancer patients were applying neoadjuvant endocrine therapy, when curative effect was complete remission, partial remission or stable, continuing to treatment, until the illness appeared progress or patients offering to stop endocrine therapy, surgical treatment. Results 6 cases of com- plete remission ,29 case of partial remission , the total effective rate was 62. 5% ; Different receptor positive patients, with ER PR double positive effect for the best, efficient 78. 38%. Conclusion New New adjuvant endocrine therapy used to treat postmenopansal hormone receptor - positive breast cancer patients have apparent curative effect, side effect was small, has the value of clinical promotion.